ライフサイエンスコーパス: death ligand

1 er several days of culture in the absence of death ligand.

2 r FADD in sensitization to IAP inhibitor and death ligands.

3 death 1 (anti-PD-1) and anti-programmed cell death ligand 1 (anti-PD-L1 ) therapy for treatment of lu

4 d anti-programmed death 1 or anti-programmed death ligand 1 (PD-1/L1) therapy.

5 t programmed cell death protein 1/programmed death ligand 1 (PD-1/PD-L1) and cytotoxic T lymphocyte-a

6 , particularly programmed death 1/programmed death ligand 1 (PD-1/PD-L1) blockade, have improved the

7 Programmed cell death protein 1:programmed death ligand 1 (PD-1:PD-L1) and cytotoxic T lymphocyte-a

8 ory checkpoint blockade with anti-programmed death ligand 1 (PD-L1) Ab can restore functions to exhau

9 ptake of (18)F-BMS-986192, a programmed cell death ligand 1 (PD-L1) adnectin PET tracer, in patients

10 The approval of anti-programmed death ligand 1 (PD-L1) and anti-programmed death 1 agent

11 We examined the expression of Programmed Death Ligand 1 (PD-L1) and defined the tumor immune micr

12 helium to upregulate cell-surface programmed death ligand 1 (PD-L1) and galectin-9.

13 These cells also express programmed death ligand 1 (PD-L1) and interleukin-10, and directly

14 nt blockade therapy targeting the programmed-death ligand 1 (PD-L1) and its receptor programmed cell

15 Blocking the interaction between Programmed Death Ligand 1 (PD-L1) and its receptor, PD-1, is an eff

16 IHC staining for programmed cell death ligand 1 (PD-L1) and mismatch repair proteins MutL

17 hat block the interaction between programmed death ligand 1 (PD-L1) and PD-1 have shown impressive an

18 blockade prevented upregulation of programed death ligand 1 (PD-L1) and PD-1 on the stimulated dendri

19 Programmed death ligand 1 (PD-L1) and PD-L2 are ligands for PD-1; t

20 s (DLBCLs) express high levels of programmed death ligand 1 (PD-L1) and PD-L2.

21 ced solid tumours expressing programmed cell death ligand 1 (PD-L1) and report here on the interim an

22 The anti-programmed death ligand 1 (PD-L1) antibody atezolizumab is clinical

23 ow that in vitro blockade of programmed cell death ligand 1 (PD-L1) by an anti-PD-L1 antibody (avelum

24 For patients with high programmed death ligand 1 (PD-L1) expression (tumor proportion scor

25 and in subgroups on the basis of programmed death ligand 1 (PD-L1) expression and human papillomavir

26 the association of efficacy with programmed death ligand 1 (PD-L1) expression and tumor mutational b

27 cell carcinoma (HNSCC), with programmed cell death ligand 1 (PD-L1) expression associated with improv

28 hibitors has been associated with programmed death ligand 1 (PD-L1) expression levels in several canc

29 Here we show that programmed death ligand 1 (PD-L1) expression on tumor cells can ren

30 Positive tumor programmed death ligand 1 (PD-L1) expression was defined as combine

31 K /ROS1), if the patient has high programmed death ligand 1 (PD-L1) expression, pembrolizumab should

32 s type I IFN signaling, increases programmed death ligand 1 (PD-L1) expression, tumor CD8(+) T cells,

33 et that required interaction with programmed death ligand 1 (PD-L1) for development.

34 acquire the coinhibitory molecule programmed death ligand 1 (PD-L1) from mature dendritic cells (mDC)

35 mmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have shown remarkable activity in

36 ng the programmed death 1 (PD-1): programmed death ligand 1 (PD-L1) immune checkpoint in lung cancer,

37 T cells upregulated expression of programmed death ligand 1 (PD-L1) in a signal transducer and activa

38 lymphocyte antigen 4 (CTLA-4) and programmed death ligand 1 (PD-L1) in an established murine transgen

39 es strengthens the association of programmed death ligand 1 (PD-L1) inhibition with this rare form of

40 ogrammed cell death protein 1 and programmed death ligand 1 (PD-L1) inhibitors to docetaxel, the curr

41 Programmed death ligand 1 (PD-L1) is an immune checkpoint protein;

42 Programmed death ligand 1 (PD-L1) is an immune regulatory ligand th

43 Programmed death ligand 1 (PD-L1) is expressed on a number of immun

44 Programmed cell death ligand 1 (PD-L1) is part of an immune checkpoint s

45 r, virus-induced dysregulation of programmed death ligand 1 (PD-L1) may play a role.

46 d the constituent proteins of the programmed-death ligand 1 (PD-L1) microenvironment in live lymphocy

47 commonly assessed biomarker programmed cell death ligand 1 (PD-L1) nor tumor mutational burden diffe

48 upregulate the expression of programmed cell death ligand 1 (PD-L1) on mouse immature myeloid cells (

49 The programmed cell death ligand 1 (PD-L1) participates in an immune checkpo

50 ibitory programmed death 1 (PD-1)-programmed death ligand 1 (PD-L1) pathway contributes to the functi

51 cell death protein 1 (PD-1)/programmed cell death ligand 1 (PD-L1) pathway is a negative regulator o

52 cking programmed death receptor 1/programmed death ligand 1 (PD-L1) signaling have radically improved

53 ation was stratified according to programmed death ligand 1 (PD-L1) status, BRAF mutation status, and

54 ical breast cancer stage and programmed cell death ligand 1 (PD-L1) status.

55 Administration (FDA) detect programmed cell death ligand 1 (PD-L1) to enrich for patient response to

56 192, an adnectin-based human programmed cell death ligand 1 (PD-L1) tracer, was developed to noninvas

57 non-small-cell lung cancer with a programmed death ligand 1 (PD-L1) tumour proportion score (TPS) of

58 stance via CD4(+) T-cell loss and programmed death ligand 1 (PD-L1) upregulation challenge this conce

59 found a higher frequency of programmed cell death ligand 1 (PD-L1)(+) germinal center B cells from l

60 ' signals-including CD47(1), programmed cell death ligand 1 (PD-L1)(2) and the beta-2 microglobulin s

61 gram cell death protein 1 (PD-1), programmed death ligand 1 (PD-L1), and cytotoxic T lymphocyte-assoc

62 ne 2,3-dioxygenase (IDO) and programmed cell death ligand 1 (PD-L1), and resulted in good outcomes.

63 express the ligand for PD-1, programmed cell death ligand 1 (PD-L1), facilitating their escape from t

64 te lower expression of inhibitory programmed death ligand 1 (PD-L1), HMPV-specific CD8(+) T cells of

65 ntibody that binds selectively to programmed death ligand 1 (PD-L1), in this patient population.

66 ors of T-cell activation, such as programmed death ligand 1 (PD-L1), programmed death 1 ligand 2 (PD-

67 ress IgA, interleukin (IL)-10 and programmed death ligand 1 (PD-L1), the appearance of which depends

68 s, such as the expression of programmed cell death ligand 1 (PD-L1), the inhibition of which results

69 of the coinhibitory molecule programmed cell death ligand 1 (PD-L1), the ligand for PD-1, which is fu

70 raction with the B7 family member programmed death ligand 1 (PD-L1), which is substantially expressed

71 reatment option for patients with programmed death ligand 1 (PD-L1)-expressing advanced non-small-cel

72 ith chemotherapy in patients with programmed death ligand 1 (PD-L1)-positive NSCLC.

73 as surface expression of CD86 and programmed death ligand 1 (PD-L1).

74 ured and fetal liver HSCs express programmed death ligand 1 (PD-L1).

75 d and neck cancers (HNC), express programmed death ligand 1 (PD-L1).

76 s defined by status regarding the programmed death ligand 1 (PD-L1).

77 f the immunosuppressive protein - programmed death ligand 1 (PD-L1).

78 Recently, agents targeting the programmed death ligand 1 (PD-L1)/programmed death receptor 1 (PD-1

79 Programmed death ligand 1 (PD-L1, also called B7-H1) is an immune c

80 Programmed death ligand 1 (PD-L1, also known as B7 homolog 1 or CD2

81 antigen 4 (CTLA-4/CD152) and programmed cell death ligand 1 (PDL1/CD274) showed clinical efficacy in

82 therapy with anti-CTLA-4 and anti-programmed death ligand 1 Abs, even when checkpoint blockade alone

83 Blockade of programmed death ligand 1 and 2, but not CD40, TGF-beta signaling,

84 ependent upon the balance between programmed death ligand 1 and IL-12 expression.

85 microcirculation and mapping out programmed-death ligand 1 and programmed cell death protein 1 in tu

86 n kinase B-Raf inhibitor and anti-programmed death ligand 1 antibody elicited higher local TAM levels

87 Blocking the programmed death ligand 1 binding site just before i.v. injection o

88 and sensitize tumors to PD-1/programmed cell death ligand 1 blockade-induced rejection.

89 s largely unaffected by PD-1/programmed cell death ligand 1 blockade.

90 ll death protein 1 (PD-1) or programmed cell death ligand 1 can enhance effector T-cell responses.

91 ly, these LP DCs upregulated programmed cell death ligand 1 during the initial interaction with MOG-s

92 100; P < .001) and increased programmed cell death ligand 1 expression (0 vs 1.5; P < .001) in the im

93 by tumor-infiltrating T cells and programmed death ligand 1 expression in the prostate, disrupting pr

94 P3C stimulation did not induce programmed death ligand 1 expression on LSECs, thereby favoring T c

95 te/proinflammatory, and increased programmed death ligand 1 expression on natural killer cells (incre

96 T3 mRNA increase, as well as programmed cell death ligand 1 expression, accompanied by a putatively c

97 atment tumor CD8 cell density and programmed death ligand 1 expression, whereas all nonresponders did

98 ur microenvironment and increased programmed death ligand 1 expression.

99 T cell infiltration and prominent programmed death ligand 1 expression.

100 te, disrupting programmed death 1/programmed death ligand 1 interaction did not enhance T cell functi

101 Inactivation of either programmed death ligand 1 or IFNGR1 elicited a robust anti-tumour a

102 of ICOS or the programmed death-1/programmed death ligand 1 pathway was shown to abolish the regulati

103 her find that upregulation of the programmed death ligand 1 protein-a key checkpoint molecule-in mreg

104 inally, programed death protein 1/programmed death ligand 1 signaling pathways were essential in pote

105 ession of the inhibitory molecule programmed death ligand 1 that, through interaction with programmed

106 Tfh cells consistently expressed programmed death ligand 1 upon activation.

107 lation of OX40 ligand (OX40L) and programmed death ligand 1(PD-L1) expression.

108 PD-L1 (programmed death ligand 1) and PD-L2 are cell-surface glycoproteins

109 ted genes involved in PD-1-PD-L1 (programmed death ligand 1) and T cell cytotoxicity pathways.

110 ng PD-1/PD-L1 (programmed death-1/programmed death ligand 1) interactions-is showing impressive clini

111 oxic T-lymphocyte antigen 4, anti-programmed death ligand 1) or proinflammatory cytokines (interleuki

112 expression of the protein PD-L1 (programmed death ligand 1).

113 such as programmed death 1 (PD1)/programmed death ligand 1, leading to T cell exhaustion and providi

114 Conclusion In patients with programmed death ligand 1-positive advanced cervical cancer, pembro

115 d efficacy of pembrolizumab in 20 programmed death ligand 1-positive, advanced solid tumor cohorts.

116 ional FOXP3(+) Treg cells through programmed death ligand 1.

117 an leukocyte antigen class II and programmed death ligand 1.

118 duces Treg expression of CD39 and programmed death ligand 1.

119 expression of programmed death 1/programmed death ligand 1.

120 tact-dependent manner mediated by programmed death ligand 1.

121 nalyzed for T-cell infiltrate and programmed death ligand 1.

122 eukocyte antigen-DR (HLA-DR), and programmed death ligand 1/2 (PDL1/2) measured on pDCs.

123 ssive microenvironment, including programmed death ligand 1/2 and chemokine (C-C motif) ligand 17.

124 had increased expression of CD48, programmed death ligand 1/2, and CD70.

125 death 1 (PD-1) blockade induced a programmed death ligand 1/NOD-, LRR-, and pyrin domain-containing p

126 mmed death 1 (anti-PD-1) and anti-programmed death-ligand 1 (anti-PD-L1) therapy, has become an incre

127 nt signal axis programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) can effectively regulate the

128 To investigate the expression of programmed death-ligand 1 (PD-L1) and immune checkpoints and their

129 aptive resistance by upregulating programmed death-ligand 1 (PD-L1) and resulted in tumor relapse.

130 PVHA increased the uptake of anti-programmed death-ligand 1 (PD-L1) antibody in HA-accumulating anima

131 olizumab (MPDL3280A), a humanized programmed death-ligand 1 (PD-L1) antibody, in renal cell carcinoma

132 hanced when combined with an anti-programmed death-ligand 1 (PD-L1) antibody.

133 Durable tumor immunity required programmed death-ligand 1 (PD-L1) blockade in combination with an a

134 that influence responsiveness to programmed death-ligand 1 (PD-L1) blockade.

135 Blockade of programmed death-ligand 1 (PD-L1) by therapeutic antibodies has sho

136 Programmed death-ligand 1 (PD-L1) down-modulates various immune res

137 evaluated the prognostic value of programmed death-ligand 1 (PD-L1) expression in CTCs in colorectal

138 he immune suppression mediated by programmed death-ligand 1 (PD-L1) expression on cancer cells accomp

139 It is now recognized that programmed death-ligand 1 (PD-L1) expression on cancer cells is a c

140 Programmed death-ligand 1 (PD-L1) expression on malignant cells is

141 asive immuno-PET imaging of human programmed death-ligand 1 (PD-L1) expression, in a preclinical mode

142 umor-infiltrating lymphocytes and programmed death-ligand 1 (PD-L1) expression.

143 y of avelumab, a fully human anti-programmed death-ligand 1 (PD-L1) IgG1 antibody, in patients with r

144 he programmed cell death 1 (PD-1)/programmed death-ligand 1 (PD-L1) immune checkpoint augments antitu

145 he programmed cell death 1 (PD-1):programmed death-ligand 1 (PD-L1) immune checkpoint pathway have us

146 The programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) immunosuppressive pathway is ofte

147 mmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) in 15 representative FFPE tumor s

148 and 9 and 10 (CXCL9, CXCL10)) and programmed death-ligand 1 (PD-L1) in clinical TNBC specimens.

149 d a heterogeneous distribution of programmed death-ligand 1 (PD-L1) in Her2 transgenic mouse mammary

150 s (TAMs) as the primary source of programmed death-ligand 1 (PD-L1) in human and murine CCA.

151 n of the immunoinhibitory molecule Programed death-ligand 1 (PD-L1) in human and murine fibroblasts i

152 f Toll-like receptor 2 (TLR2) and programmed death-ligand 1 (PD-L1) in regulating alpha-(1,3)-glucan-

153 We hypothesize the programmed death-ligand 1 (PD-L1) inhibitor, durvalumab, olaparib,

154 combining gemcitabine and a novel programmed death-ligand 1 (PD-L1) inhibitor, termed MN-siPDL1.

155 Programmed death-ligand 1 (PD-L1) is a key factor influencing cance

156 Purpose Expression of programmed death-ligand 1 (PD-L1) is a potential predictive marker

157 As we found that programmed death-ligand 1 (PD-L1) is highly expressed on glioma-ass

158 Atezolizumab is a humanised antiprogrammed death-ligand 1 (PD-L1) monoclonal antibody that inhibits

159 l of LXA4 treatment in regulating programmed death-ligand 1 (PD-L1) on KSHV-carrying tumor cells.

160 the ICPs analyzed, expression of programmed death-ligand 1 (PD-L1) on tumor and infiltrating T cells

161 d cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1) pathway play an important immunos

162 of the immune checkpoint protein programmed death-ligand 1 (PD-L1) protected HILO xenografts such th

163 ombining MEK inhibition with anti-programmed death-ligand 1 (PD-L1) resulted in synergistic and durab

164 kers of response as determined by programmed death-ligand 1 (PD-L1) status, and on-therapy quality-of

165 l lung cancer (NSCLC) with a programmed cell death-ligand 1 (PD-L1) tumour proportion score of 50% or

166 NA-mediated induced expression of Programmed Death-Ligand 1 (PD-L1) which inhibits T-cell proliferati

167 Inhibition of programmed death-ligand 1 (PD-L1) with atezolizumab can induce dura

168 arkedly reduced the expression of programmed death-ligand 1 (PD-L1), a negative regulator of cytotoxi

169 ammed cell death protein 1 (PD1), programmed death-ligand 1 (PD-L1), and B and T lymphocyte attenuato

170 All GTT subtypes express programmed death-ligand 1 (PD-L1), and natural killer (NK) cells ar

171 cells (HSCs) suppress T cells via programmed death-ligand 1 (PD-L1), but it remains unknown whether t

172 nd blocking its canonical ligand, programmed death-ligand 1 (PD-L1), lengthened the duration of migra

173 Programmed death-ligand 1 (PD-L1), which exerts T cell suppression

174 rall population and in those with programmed death-ligand 1 (PD-L1)-positive tumors.

175 ulating proteins, one of which is programmed death-ligand 1 (PD-L1).

176 illance via stabilization of programmed cell death-ligand 1 (PD-L1).

177 n translation of mRNAs, including programmed-death-ligand 1 (PD-L1).

178 renal cell carcinoma who express programmed death-ligand 1 (PD-L1).

179 of the T cell negative regulator programmed death-ligand 1 (PD-L1, also called B7-H1) can enhance T

180 Programmed death-ligand 1 (PD-L1; also called B7-H1 or CD274), whic

181 ication through the expression of programmed death-ligand 1 (PD-L1; also called CD274 or B7-H1) in th

182 roves the therapeutic efficacy of programmed death-ligand 1 (PD-L1; also known as B7-H1) checkpoint b

183 activated T cells and its ligand, programmed death-ligand 1 (PD-L1; encoded by the CD274 gene), is a

184 lowing immune restoration by anti-programmed death-ligand 1 (PDL1) blockade.

185 study assessed atezolizumab (anti-programmed death-ligand 1 [PD-L1]) as treatment for metastatic urot

186 nd efficacy of atezolizumab (anti-programmed death-ligand 1 [PD-L1]) versus chemotherapy in this pati

187 ages (TAMs) that expressed CD274 (programmed death-ligand 1 [PD-L1]), TGF-beta activation, and an imm

188 ased, with elevated expression of programmed death-ligand 1 and IL-10, and decreased expression of in

189 Anti-programmed death-ligand 1 antibody (aPDL1), an immune checkpoint in

190 Tumor programmed death-ligand 1 expression and MSI-H/MMR-D status were no

191 gher-level Hodgkin Reed-Sternberg programmed death-ligand 1 expression had more favorable responses t

192 t exhibited impaired induction of programmed death-ligand 1 expression in a wide range of human cance

193 anticancer effect on reduction of programmed death-ligand 1 expression in LL/2 cells.

194 Programmed death-ligand 1 expression on tumor cells and ICs, PD-L1

195 Chromosome 9p24.1 alterations and programmed death-ligand 1 expression were assessed in Hodgkin Reed-

196 thods Patients were stratified by programmed death-ligand 1 expression, BRAF status, and best prior c

197 mor-infiltrating T cells, but not programmed death-ligand 1 expression, in tumor tissue correlated wi

198 fficacy was correlated with tumor programmed death-ligand 1 expression, microsatellite-high and/or mi

199 r programmed cell death protein 1/programmed death-ligand 1 have displayed durable clinical responses

200 Focal induction of programmed death-ligand 1 in the tumor microenvironment, enhanced c

201 In return, programmed death-ligand 1 interacts with the constitutively express

202 istration induces upregulation of programmed death-ligand 1 on dendritic cells in a T cell-dependent

203 , but not those of CD80, CD86, or programmed death-ligand 1 or 2, correlated with T cell responsivene

204 grammed cell death protein-1/programmed cell death-ligand 1 pathway inhibition are needed to evaluate

205 grammed cell death protein-1/programmed cell death-ligand 1 pathway inhibition in sepsis, BMS-936559

206 Tumor size and programmed death-ligand 1 status were among the baseline factors in

207 h cannot recognize peptidoglycan, programmed death-ligand 1 was undetected.

208 ne tolerance-associated molecule 'programmed death-ligand 1', whereas in NOD1/2 double knockout mice,

209 ainst the programmed cell death-1/programmed death-ligand 1(PD-1/PD-L1) protein-protein interaction (

210 ssion of immune modulators PD-L1 (programmed death-ligand 1) and CD86 by myeloid DCs (mDCs) and decre

211 ion levels of the CD274 molecule (programmed death-ligand 1) and programmed cell death 1, markers of

212 differentiation 8), CD68, PD-L1 (programmed death-ligand 1), CD34, FAP (fibroblast activation protei

213 adaptive immune checkpoint PD-L1 (programmed death-ligand 1).

214 ytes, cyclin E, adipophilin, programmed cell death-ligand 1, and elastase staining and other patient,

215 tory pathways in T cells, such as programmed death-ligand 1, programmed cell death 1, or transforming

216 cells and enhanced expression of programmed death-ligand 1, whose expression on monocytes and dendri

217 growth factor receptor, CD71 and programmed death-ligand 1.

218 paB activity, and upregulation of programmed death-ligand 1.

219 IgM expression (67%), and lack of programmed death-ligand 1/ligand 2.

220 but comparatively high levels of programmed death ligand-1 (B7-H1), and were resistant to pro-inflam

221 ells, with elevated expression of programmed death ligand-1 (PD-1) and lymphocyte activation gene-3 (

222 tanding of the programmed death-1/programmed death ligand-1 (PD-1/PD-L1) pathway (referred to as the

223 impairment via programmed death-1/programmed death ligand-1 (PD-1/PD-L1) signaling, a pathway previou

224 naling through programmed death-1/programmed death ligand-1 (PD-1/PD-L1), but not through cytotoxic T

225 Programmed death ligand-1 (PD-L1) and cluster of differentiation 80

226 Signaling via programmed death ligand-1 (PD-L1) and PD-L2 is crucial for maintain

227 Extracellular interaction between programmed death ligand-1 (PD-L1) and programmed cell death protein

228 f antibody therapeutics targeting programmed death ligand-1 (PD-L1) can be quantified noninvasively.

229 ammed cell death protein-1 (PD-1)/programmed death ligand-1 (PD-L1) checkpoint blockade has led to re

230 ession of the coinhibitory ligand programmed death ligand-1 (PD-L1) concurrent with enrichment of the

231 Rs reduced immunosuppressive programmed cell death ligand-1 (PD-L1) expression by downregulating EGFR

232 IFN-gamma is a critical driver of programmed death ligand-1 (PD-L1) expression in cancer and host cel

233 nst programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) have shown little efficacy in pat

234 ed cell death protein-1 (PD-1) to programmed death ligand-1 (PD-L1) have shown marked efficacy agains

235 Aberrant expression of programmed death ligand-1 (PD-L1) in tumor cells promotes cancer pr

236 Programmed death ligand-1 (PD-L1) interaction with PD-1 induces T c

237 Programmed death ligand-1 (PD-L1) interacts with programmed death-1

238 Programmed death ligand-1 (PD-L1) is a critical regulator of T cell

239 a negative costimulatory molecule programmed death ligand-1 (PD-L1) is defective in SLE patients with

240 Programmed cell death ligand-1 (PD-L1) is typically produced by cancer c

241 via the programmed death-1 (PD-1)-programmed death ligand-1 (PD-L1) pathway.

242 Programmed death ligand-1 (PD-L1) plays a critical role in T-cell r

243 eat biopsy for assessment of programmed cell death ligand-1 (PD-L1) status.

244 pe and increase the expression of programmed death ligand-1 (PD-L1) when treated with reactive oxygen

245 between PD-1 and its ligand programmed cell death ligand-1 (PD-L1) with monoclonal antibodies has sh

246 population exhibiting the markers programmed death ligand-1 (PD-L1), Mac-2, and macrophage mannose re

247 this model, loss of PD-1, but not programmed death ligand-1 (PD-L1), on the antigen-specific CD4(+) T

248 jor mechanism is the induction of programmed death ligand-1 (PD-L1), which mitigates adaptive immune

249 Th cells, total macrophages, and programmed death ligand-1 (PD-L1)-positive immune-suppressive macro

250 ell as the expression of the programmed cell death ligand-1 (PD-L1/CD274), was recently described.

251 e immune inhibitory molecule programmed cell death ligand-1 (PD-L1; also known as B7-H1), in a manner

252 uring persistent viral infection, programmed death ligand-1 (PDL-1) also stimulates the expansion of

253 unity through their expression of programmed death ligand-1 (PDL1 or B7-H1), which interacts with T c

254 but they did express higher programmed cell death ligand-1 (PDL1) than other neutrophils, and lympho

255 nd/or programmed death-1 receptor/programmed death ligand-1 [PD-(L)1] inhibitor, including a cohort o

256 f the immune checkpoint inhibitor programmed death ligand-1 and accumulation of T-regulatory cells an

257 Programmed cell death-1 (PD-1)/programmed death ligand-1 blockade may potentially augment graft-vs

258 , our data suggest that PD-1/programmed cell death ligand-1 blockade using soluble rPD-1-Fc instead o

259 were achieved regardless of tumor programmed death ligand-1 expression.

260 rvival (OS) and response by tumor programmed death ligand-1 expression.

261 ogrammed cell death-1 (PD-1)/programmed cell death ligand-1 pathway has been shown to limit cell-medi

262 riments, antibody blockade of the programmed death ligand-1 receptor programmed death receptor-1 (PD-

263 was, in contrast to inhibition by programmed death ligand-1-Fc, not overcome by anti-CD28 costimulati

264 roved PFS and OS in patients with programmed death ligand-1-positive tumors.

265 therapy but not with anti-PD-1 or programmed death ligand-1.

266 n molecules CD80, CD83, CD40, and programmed death ligand-1.

267 tein-1 (PD-1) (-6.8 kcal/mol) and programmed death-ligand-1 (PD-L1) (-9.6 kcal/mol).

268 e programmed death-1 and monocyte programmed death-ligand-1 expression in most studies.

269 or cells (and their expression of programmed-death-ligand-1) in spinal cord-draining lymph nodes and

270 We report that programmed death ligand 2 (PD-L2), a known ligand of PD-1, also bin

271 moting IFN regulatory factor 4(+) programmed death ligand 2(+) dendritic cells and ILT3(+) rebounded

272 e costimulator ligand) and PD-L2 (programmed death ligand 2).

273 CII(hi) DC revealed expression of programmed death ligand 2, CD301b, IFN regulatory factor 4, and mod

274 luding IL-10, TGF-beta1, IDO, and programmed death ligand 2, T. cruzi infection induced an early incr

275 Low programmed death-ligand 2 (PD-L2) was the most sensitive/specific m

276 ce expression of CD11c, CD73, and programmed death-ligand 2.

277 TNF superfamily death ligands are expressed on the surface of immune cel

278 lated apoptosis-inducing ligand (TRAIL) is a death ligand cytokine known for its cytotoxic activity a

279 ce death receptors, which respond to cognate death ligands expressed on immune-effector cells.

280 hepatic NK cells, surface expression of the death ligand FasL, and capacity to kill FasL-sensitive t

281 tead CXCR6+ NK could upregulate TRAIL, a key death ligand in hepatitis pathogenesis.

282 further enhanced by physiologically relevant death ligands including TNF-related apoptosis inducing l

283 ibody-mediated disruption of PD-1/programmed death ligand interaction.

284 mulatory molecules of DCs such as programmed death ligands, OX40 ligand, and inducible T-cell costimu

285 Moreover, we have identified programmed cell death ligand (PD-L) 2 as a negative regulator of TH9 cel

286 in IL-10 and higher expression of programmed death ligand (PD-L)1 and PD-L2 - which were partially de

287 FN)-gamma, programed death (PD)-1, programed death ligand (PD-L)1, and the suppression of hepatitis B

288 timulatory molecules, such as the programmed death ligand (PD-L1), might exert differential effects o

289 We studied program death-ligand (PD-L)1 in neurons and gliomas in tumors fr

290 romoting the tolerogenic markers, programmed death-ligand (PD-L)1, PD-L2, and the tryptophan degradin

291 dization here, we report that the programmed death ligand (PDL) locus (9p24.1) is frequently and spec

292 Programmed death ligands (PDLs) are immune-regulatory molecules tha

293 Because Mincle can ligate the cell death ligand SAP130, we postulated that Mincle signaling

294 dentical to drug-naive cells with respect to death ligand sensitivity and gene expression profiles.

295 In particular, death ligands such as tumour necrosis factor (TNF)-alpha

296 lated apoptosis-inducing ligand (TRAIL) is a death ligand that can induce apoptosis in cells expressi

297 ature NK cells constitutively expressing the death ligand TRAIL depended on T-bet.

298 The ability of the death ligand TRAIL to induce tumor cell apoptosis has le

299 cinoma (CCA) cells paradoxically express the death ligand tumor necrosis factor-related apoptosis-ind

300 ivity of cancer cells to TRAIL, a TNF family death ligand with promising therapeutic potential, act b